Ontology highlight
ABSTRACT: Importance of the field
Alzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available. Immunotherapy directed against the beta-amyloid peptide may be capable of slowing the rate of disease progression. Bapineuzumab, an anti-beta-amyloid monoclonal antibody, will be the first such agent to emerge from Phase III clinical trials.Areas covered in this review
The primary literature on bapineuzumab from 2009 and 2010 is reviewed in its entirety, along with the literature on AN1792, a first-generation anti-beta-amyloid vaccine, from 2003 to 2009. Other Alzheimer's disease immunotherapeutics currently in development, according to www.clinicaltrials.gov , are also discussed.What the reader will gain
In addition t
SUBMITTER: Kerchner GA
PROVIDER: S-EPMC3000430 | biostudies-literature | 2010 Jul
REPOSITORIES: biostudies-literature